Results 111 to 120 of about 58,626 (275)

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Plant‐derived extracellular vesicle‐like particles as novel osteoanabolic agents: Activating bone morphogenetic protein 2/Smads signaling axis for bone regeneration in postmenopausal osteoporosis

Interdisciplinary Medicine, EarlyView.
Illustration depicting the isolation of Dipsaci Radix derived extracellular vesicle‐like particles and their function in alleviating osteoporosis. (A) Extraction and characterization detection process of extracellular vesicle‐like particles derived from Dipsaci Radix roots. (B) Cell experiments in vitro, Dipsaci Radix derived extracellular vesicle‐like
Qing Zhao, Yue Cao, Zhengting Wu, Yingqi Cao, Qi You, Yuanyuan Xia, Xuejun Tan, Dongxiao Li, Tianxin Qiu, Xiuping Cai, Zhaodi Guo, Lei Zheng, Kewei Zhao   +12 more
wiley   +1 more source

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens

Blood Neoplasia
: Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm for which hematopoietic stem cell transplantation is the only curative treatment.
Shannalee Martinez, Vladimir V. Senyukov, Suheyla Hasgur, Arianexys Aquino-López, Peter D. Emanuel, Y. Lucy Liu, Elliot Stieglitz, Gregory Behbehani, Amanda R. Campbell, Dean A. Lee   +9 more
doaj   +1 more source

The use of donor-derived veto cells in hematopoietic stem cell transplantation

Frontiers in Immunology, 2012
The induction of immune tolerance by specific agents, as opposed to general immune suppression, is a most desirable goal in transplantation biology. One approach to attain this goal is afforded by the use of donor-derived cells endowed with veto activity,
Eran eOphir, Yair eReisner
doaj   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Quantification of intrinsic regulatory factors refines human hematopoietic progenitor definitions and reveals early erythroid lineage priming

Cell Reports
Summary: Hematopoietic stem and progenitor cell (HSPC) transplantation is an essential therapy for hematological conditions, but finer definitions of human HSPC subsets with associated function could enable better tuning of grafts and more routine, lower-
Patricia Favaro, David R. Glass, Luciene Borges, Reema Baskar, Avery Lam, Warren Reynolds, Daniel Ho, Trevor Bruce, Dmitry Tebaykin, Thomas Koehnke, Vanessa M. Scanlon, Ilya Shestopalov, Sean C. Bendall   +12 more
doaj   +1 more source

Expression of CD34 antigen in organoid nervus causing the secondary tumor.

Skin Cancer, 1996
The human CD34 surface antigen is expressed on hematopoietic stem / progenitor cells. In the skin, vascular endothelial cells and mesenchymal cells including dermal dendritic cells and perifollicular cells are stained with the anti-CD34 monoclonal antibody. Interestingly, other than those mesenchymal cells in the dermis, the outer-root sheath enithelia
Koji UEDE, Masahiro MATSUNAKA
openaire   +2 more sources

Brain Pericytes and Wnt/β‐Catenin Signaling Induce Functional Blood–Brain Barrier Phenotype in Human iPSC‐Derived Model

Small Methods, EarlyView.
This study shows that human iPSC‐derived endothelial cells acquire a functional blood–brain barrier phenotype when co‐cultured with brain pericytes and stimulated with CHIR‐99021, a Wnt/β‐catenin activator. This model recapitulates key barrier properties, inflammatory responses, and transcriptomic features of the native human BBB, offering new ...
Henrique Nogueira Pinto, Nine R. Kok, Philipp C. Hauger, Manon Karsten‐van Diepen, Michael de Kok, Nanne J. Paauw, Susanne M. A. van der Pol, Joline P. Nugteren‐Boogaard, Peter L. Hordijk, Stephanie D. Beekhuis‐Hoekstra, Susan Gibbs, Nienke M. de Wit, Helga E. de Vries   +12 more
wiley   +1 more source

Prostatic stromal tumors with uncertain malignant potential: A scoping review of clinical challenges and management strategies

UroPrecision, EarlyView.
Abstract Prostatic stromal tumor of uncertain malignant potential (STUMP) is a rare neoplasm arising from specialized prostatic stromal cells with a broad range of histologic patterns and unpredictable clinical behavior. It is often challenging to distinguish STUMP from prostatic stromal sarcoma due to morphological similarities, necessitating specific
Ibrahim A. Khalil, Abdullah M. Al‐Jubouri, Khaled Murshed, Ahmad R. Al‐Qudimat, Majd Alkabbani, Nagy Younes, Khalid Al Jalham, Khalid Al Rumaihi   +7 more
wiley   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source